Company
Zenas (NASDAQ: ZBIO)
Enabling patients with autoimmune diseases to reimagine life
Also known as Zenas BioPharma, Zenas BioPharma, Inc.
- Business model
- B2B
- Legal name
- Zenas BioPharma, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
We are a proven team dedicated to developing therapies for autoimmune diseases with significant opportunities to address unmet patient needs and transform lives.
Funding snapshot
- Total raised
- $384MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $200M2024-05-03
Funding rounds
- Round, 2024
- $200M2024-05-03, SEC form D sold, 26 investors
- Round, 2022
- $184M2022-11-02, SEC form D sold, 17 investors
Loading relationship preview